Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
| ▸ | MAG | P20916 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975418 | 0.94 | TP53 (0.45) | POLBLGALS3TP53MDM2HRAS | |
| SCHEMBL13130031 | 0.87 | PTPN1 (0.45) | GJB2 | |
| SCHEMBL15975417 | 0.87 | GJB2 (0.41) | TP53MDM2GJB2 | |
| SCHEMBL16489968 | 0.86 | SLC6A2 (0.44) | POLBLGALS3HRASCD69 | |
| SCHEMBL11170193 | 0.86 | MAG (0.49) | POLBLGALS3TP53MDM2HRAS | |
| SCHEMBL11170198 | 0.86 | MAG (0.49) | POLBLGALS3TP53MDM2HRAS | |
| SCHEMBL11494535 | 0.86 | MAG (0.49) | POLBLGALS3TP53MDM2HRAS | |
| SCHEMBL13130039 | 0.86 | LMNA (0.43) | POLBLGALS3TP53MDM2GJB2 | |
| SCHEMBL15975416 | 0.86 | LMNA (0.43) | POLBLGALS3TP53MDM2GJB2 | |
| SCHEMBL13129953 | 0.82 | MAG (0.45) | LGALS3TP53MDM2LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815239-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | POLB 4459/4885LGALS3 9/4885TP53 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.